Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

NCT07074977 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Pruritus of Unknown Origin

Interventions

DRUG: nemolizumab
DRUG: Placebo

Sponsor

Galderma R&D